Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 234-242

  Abel, E Dale ^a   Doenst, Torsten ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cardiac hypertrophy; Heart failure; Mitochondria; Signal transduction

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARDIOLIPIN; ESTROGEN RELATED RECEPTOR ALPHA; FATTY ACID; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; PROTEOME; REACTIVE OXYGEN METABOLITE;

ADAPTATION; ARTICLE; CELL ENERGY; CELL FUNCTION; CELL ORGANELLE; CELL STRUCTURE; ENERGY CONSUMPTION; EXERCISE TEST; FATTY ACID OXIDATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE UTILIZATION; HEART AFTERLOAD; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART PRELOAD; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERVOLEMIA; LIPOTOXICITY; MITOCHONDRION; NONHUMAN; PATHOLOGICAL HEART VENTRICLE HYPERTROPHY; PHYSIOLOGICAL HEART VENTRICLE HYPERTROPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CARDIOMEGALY; HEART; HUMANS; MITOCHONDRIA; MYOCARDIAL CONTRACTION; SIGNAL TRANSDUCTION;

EID: 79955391768     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr015     Document Type: Article

References (108)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
2. Papademetriou V. From hypertension to heart failure. J Clin hypertens (Greenwich) 2004;6:14-17.
3. Liu SK, Magid NR, Fox PR, Goldfine SM, Borer JS. Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation. Cardiology 1998;90: 101-109. (Pubitemid 28486685)
4. Bristow MR. Mechanisms ofdevelopment of heartfailure in the hypertensive patient. Cardiology 1999;92(Suppl. 1):3-6; discussion 7-9, 20-21.
5. Carabello BA. Aortic stenosis: from pressure overload to heartfailure. Heart Fail Clin 2006;2:435-442. (Pubitemid 46590079)
6. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 2005;26:1790-1796. (Pubitemid 41222328)
7. Fagard R. Athlete's heart. Heart 2003;89:1455-1461. (Pubitemid 37465249)
8. Naylor LH, George K, O'Driscoll G, Green DJ. The athlete's heart: a contemporary appraisal ofthe 'Morganroth hypothesis'. Sports Med 2008;38:69-90. (Pubitemid 350261960)
9. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 1998;39:60-76. (Pubitemid 28322380)
10. Monnet E, Chachques JC. Animal models of heart failure: what is new? Ann Thorac Surg 2005;79:1445-1453. (Pubitemid 40431897)
11. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M et al. Pro-teomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res 2010;85:376-384.
12. Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 2010;86:461-470.
13. Zaha V, Grohmann J, Gobel H, Geibel A, Beyersdorf F, Doenst T. Experimental model for heart failure in rats\induction and diagnosis. Thoracic Cardiovasc Surg 2003;51:211-215. (Pubitemid 37229335)
14. Swoap SJ, Boddell P, Baldwin KM. Interaction ofhypertension and caloric restriction on cardiac mass and isomyosin expression. Am J Physiol 1995;268:R33-R39.
15. Wiesel P, Patel AP, Carvajal IM, Wang ZY, Pellacani A, Maemura K et al. Exacer-bation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice. Circ Res 2001;88:1088-1094. (Pubitemid 34137123)
16. Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, Lopaschuk GD et al. Calorie restriction prevents hypertension and cardiac hypertrophy in the spon-taneously hypertensive rat. Hypertension 2010;56:412-421.
17. Miyachi M, Yazawa H, Furukawa M, Tsuboi K, Ohtake M, Nishizawa T et al. Exercise training alters left ventricular geometry and attenuates heart failure in dahl salt-sensitive hypertensive rats. Hypertension 2009;53:701-707.
18. Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS. Characterization of cardiac hypertrophy and heart failure due to volume overload in the ratJ Appl Physiol 2003; 94:752-763. (Pubitemid 36158255)
19. Magid NM, Opio G, Wallerson DC, Young MS, Borer JS. Heart failure due to chronic experimental aortic regurgitation. Am J Physiol 1994;267:H556-H562. (Pubitemid 24272472)
20. McMullen JR, Jennings GL Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Phar-macol Physiol 2007;34:255-262.
21. Halson SL, Jeukendrup AE. Does overtraining exist? An analysis of overreaching and overtraining research. Sports Med 2004;34:967-981. (Pubitemid 39665190)
22. Molkentin JD, Robbins J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol 2009;46: 130-136.
23. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactiva-tor 1alpha. Proc Natl Acad Sci USA 2006;103:10086-10091. (Pubitemid 43993627)
24. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008;118:3588-3597.
25. O'Neill BT, Kim J, Wende AR, Theobald HA, Tuinei J, Buchanan J et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adap-tations that accompany physiological cardiac hypertrophy. Cell Metab 2007;6: 294-306. (Pubitemid 47450187)
26. Rimbaud S, Garnier A, Ventura-Clapier R. Mitochondrial biogenesis in cardiac patho-physiology. Pharmacol Rep 2009;61:131-138.
27. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207-258.
28. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106:606-612. (Pubitemid 34827712)
29. van Bilsen M, van Nieuwenhoven FA, van derVusse GJ. Metabolic remodelling ofthe failing heart: beneficial or detrimental? Cardiovasc Res 2009;81:420-428.
30. Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem 2008;311:215-224.
31. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxi-some proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-1730. (Pubitemid 30421753)
32. Rimbaud S, Sanchez H, Garnier A, Fortin D, Bigard X, Veksler V et al. Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol 2009;46:952-959.
33. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF et al. Recruitment ofcompensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metab-olism in hypertrophied hearts. Circulation 2007;115:2033-2041. (Pubitemid 46625954)
34. Degens H, de Brouwer KF, Gilde AJ, Lindhout M, Willemsen PH, Janssen BJ et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 2006;101:17-26. (Pubitemid 43323428)
35. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Fujii N, Miyazaki H et al. Cardiac hypertro-phy by hypertension and exercise training exhibits different gene expression of enzymes in energy metabolism. Hypertens Res 2003;26:829-837. (Pubitemid 37406952)
36. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010;3:420-430.
37. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994;267:H742-H750. (Pubitemid 24272494)
38. Martin MA, Gomez MA, Guillen F, Bornstein B, Campos Y, Rubio JC et al. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patientswith severe heart failure. Biochim Biophys Acta 2000;1502:330-336.
39. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev2002;7:161-173. (Pubitemid 34624804)
40. Strom CC, Aplin M, Ploug T, Christoffersen TE, Langifort J, Viese M et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005;272:2684-2695. (Pubitemid 40825416)
41. Burelle Y, Wambolt RB, Grist M, Parsons HL, Chow JC, Antler C et al. Regular exer-cise is associated with a protective metabolic phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2004;287:H1055-H1063. (Pubitemid 39096650)
42. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801: 311-319.
43. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration ofglycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009;9:512-524.
44. Floras JS. Sympathetic nervous system activation in human heart failure: clinical impli-cations of an updated model. JAm Coll Cardiol 2009;54:375-385.
45. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-1762.
46. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009;54:1637-1646.
47. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEBJ 2004;18:1692-1700. (Pubitemid 39463708)
48. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mito-chondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab 2008;295: E678-E685.
49. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MK. Mitochondrial dys-function and lipotoxicity. Biochim Biophys Acta 2010;1801:266-271.
50. Hatch GM. Regulation ofcardiolipin biosynthesis in the heart. Mol Cell Biochem 1996; 159:139-148.
51. Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 2008;65:2493-2506.
52. Chicco AJ, Sparagna GC. Role ofcardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007;292:C33-C44. (Pubitemid 46115119)
53. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species gener-ated by the mitochondrial respiratory chain affect the complex III activity via cardi-olipin peroxidation in beef-heart submitochondrial particles. Mitochondrion 2001;1: 151-159. (Pubitemid 33586026)
54. Saini-Chohan HK, Holmes MG, Chicco AJ, Taylor WA, Moore RL, McCune SA et al. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res 2009;50:1600-1608.
55. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML et al. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res 2007;48:1559-1570. (Pubitemid 47312017)
56. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium 2009;45:643-650.
57. Allard MF. Energy substrate metabolism in cardiac hypertrophy. Curr Hypertens Rep 2004;6:430-435. (Pubitemid 39600098)
58. Leong HS, Brownsey RW, Kulpa JE, Allard MF. Glycolysis and pyruvate oxidation in cardiac hypertrophy\why so unbalanced? Comp Biochem Physiol A Mol Integr Physiol 2003;135:499-513. (Pubitemid 37289111)
59. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 2000;36: 1378-1385.
60. Matlib MA, Rembert JC, Millard RW, Ashraf M, Rouslin W, Asano G et al. Mitochon-drial function in canine experimental cardiac hypertrophy. J Mol Cell Cardiol 1983;15: 221-232. (Pubitemid 13089938)
61. Gong G, Liu J, Liang P, Guo T, Hu Q, Ochiai K et al. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 2003;285:H541-H548. (Pubitemid 36885884)
62. Ye Y, Gong G, Ochiai K, Liu J, Zhang J. High-energy phosphate metabolism and cre-atine kinase in failing hearts: a new porcine model. Circulation 2001;103:1570-1576. (Pubitemid 32226267)
63. Griffiths ER, Friehs I, Scherr E, Poutias D, McGowan FX, Del Nido PJ. Electron trans-port chain dysfunction in neonatal pressure-overload hypertrophy precedes cardio-myocyte apoptosis independent of oxidative stress. J Thorac Cardiovasc Surg 2010; 139:1609-1617.
64. Jin H, Nass RD, Joudrey PJ, Lyon AR, Chemaly ER, Rapti Ket al. Altered spatiotem-poral dynamics of the mitochondrial membrane potential in the hypertrophied heart. Biophys J 2010;98:2063-2071.
65. Lin CS, Sun YL, Liu CY Structural and biochemical evidence of mitochondrial depletion in pigs with hypertrophic cardiomyopathy. Res Vet Sci 2003;74:219-226. (Pubitemid 36622115)
66. Tokoro T, Ito H, Maenishi O, Suzuki T Mitochondrial abnormalities in hypertro-phied myocardium of stroke-prone spontaneously hypertensive rats. Clin Exp Phar-macol Physiol Suppl 1995;22:S268-S269. (Pubitemid 26062098)
67. Walker JG, Bishop SP. Mitochondrial function and structure in experimental canine congestive heart failure. Cardiovasc Res 1971;5:444-450.
68. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphoryl-ation. Cardiovasc Res 2008;80:30-39.
69. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003;551:491-501. (Pubitemid 37121707)
70. Jullig M, Hickey AJ, Chai CC, Skea GL, Middleditch MJ, Costa S et al. Is the failing heart out offuel or a worn engine running rich? A study of mitochondria in old spon-taneously hypertensive rats. Proteomics 2008;8:2556-2572.
71. Marin-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res 2001;52: 103-110. (Pubitemid 32835243)
72. Marin-Garcia J, Goldenthal MJ, Moe GW. Mitochondrial pathology in cardiac failure. Cardiovasc Res 2001;49:17-26.
73. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30: 1757-1762. (Pubitemid 28430189)
74. Hang T, Huang Z, Jiang S, Gong J, Wang C, Xie D et al. Apoptosis in pressure overload-induced cardiac hypertrophy is mediated, in part, by adenine nucleotide translocator-1. Ann Clin Lab Sci 2006;36:88-95. (Pubitemid 43805884)
75. Walther T, Tschope C, Sterner-Kock A, Westermann D, Heringer-Walther S, Riad A et al. Accelerated mitochondrial adenosine diphosphate/adenosine tripho-sphate transport improves hypertension-induced heart disease. Circulation 2007; 115:333-344. (Pubitemid 46148508)
76. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hyper-trophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myo-cytes. Circ Res 2010;106:1253-1264.
77. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010;107:15565-15570.
78. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 2009;81:449-456.
79. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 2010;88: 229-240
80. Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 2006;21:250-258. (Pubitemid 44156857)
81. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115: 3213-3223. (Pubitemid 47012236)
82. Murray AJ, Cole MA, Lygate CA, Carr CA, Stuckey DJ, Little SE et al. Increased mito-chondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. J Mol Cell Cardiol 2008;44:694-700.
83. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 2002;97:203-209.
84. White FC, McKirnan MD, Breisch EA, Guth BD, Liu YM, Bloor CM. Adaptation of the left ventricle to exercise-induced hypertrophy. J Appl Physiol 1987;62: 1097-1110. (Pubitemid 17073909)
85. Huang CC, Lin TJ, Chen CC, Lin WT. Endurance training accelerates exhaustive exercise-induced mitochondrial DNA deletion and apoptosis of left ventricle myo-cardium in rats. Eur J Appl Physiol 2009;107:697-706.
86. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600. (Pubitemid 44325350)
87. Buermans HP, Redout EM, Schiel AE, Musters RJ, Zuidwijk M, Eijk PP et al. Micro-array analysis reveals pivotal divergent mRNA expression profiles early in the devel-opment of either compensated ventricular hypertrophy or heart failure. Physiol Genomics 2005;21:314-323. (Pubitemid 40898491)
88. van den Bosch BJ, Lindsey PJ, van den Burg CM, van der Vlies SA, Lips DJ, van der Vusse GJ et al. Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics 2006;88:480-488. (Pubitemid 44397446)
89. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005;115:547-555. (Pubitemid 40322224)
90. Lu Z, Xu X, Hu X, Fassett J, Zhu G, Tao Y et al. PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid redoxsignal 2010;13:1011-1022.
91. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regula-tor. Endocr Rev 2003;24:78-90. (Pubitemid 36223280)
92. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006;98:15-24. (Pubitemid 43977219)
93. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113:2579-2588. (Pubitemid 43948006)
94. Trivedi CM, Lu MM, Wang Q, Epstein JA. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem 2008;283:26484-26489.
95. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13:324-331. (Pubitemid 46376684)
96. O'Neill BT, Abel ED. Akt1 in the cardiovascular system: friend or foe?J Clin Invest 2005;115:2059-2064. (Pubitemid 41134142)
97. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordi-nated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118. (Pubitemid 41134152)
98. Boudina S, Bugger H, Sena S, O'Neill BT, Zaha VG, Ilkun O et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009;119:1272-1283.
99. Sena S, Hu P, Zhang D, Wang X, Wayment B, Olsen C et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol 2009;46:910-918.
100. Ikeda H, Shiojima I, Ozasa Y, Yoshida M, Holzenberger M, Kahn CR et al. Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy. J Mol Cell Cardiol 2009;47:664-675.
101. Kim J, Wende AR, Sena S, Theobald HA, Soto J, Sloan C et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol 2008;22:2531-2543.
102. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007;104:12017-12022. (Pubitemid 47185622)
103. Lira VA, Brown DL, Lira AK, Kavazis AN, Soltow QA, Zeanah EH et al. Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol 2010;588: 3551-3566.
104. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006;574:33-39. (Pubitemid 43905794)
105. Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG et al. Physiologic role of AMP-activated protein kinase (AMPK) in the heart: graded activation during exer-cise. Am J Physiol Endocrinol Metab 2003;285:E629-E636. (Pubitemid 37010843)
106. Kim AS, Miller EJ, Young LH. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol (Oxf) 2009;196:37-53.
107. Allard MF, Parsons HL, Saeedi R, Wambolt RB, Brownsey R. AMPK and metabolic adaptation by the heart to pressure overload. Am J Physiol Heart Circ Physiol 2007; 292:H140-H148. (Pubitemid 46115922)
108. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res 2010;106:1541-1548.